

SEQUENCE LISTING

<110> Tesaro, Inc.
 <120> METHODS OF TREATING CANCER WITH ANTI-PD-1 ANTIBODIES
 <130> TSR-006wo
 <150> 62/444,336
 <151> 2017-01-09
 <150> 62/477,423
 <151> 2017-03-27
 <150> 62/491,220
 <151> 2017-04-27
 <150> 62/556,386
 <151> 2017-09-09
 <160> 14
 <170> PatentIn version 3.5
 <210> 1
 <211> 117
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Synthetic Polypeptide
 <400> 1
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Gln Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Ser Pro Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val
 100 105 110
 Thr Val Ser Ser Ala
 115
 <210> 2
 <211> 108
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic Polypeptide

<400> 2

Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Tyr Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr Ser Ser Tyr Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg
100 105

<210> 3

<211> 443

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Polypeptide

<400> 3

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Gln Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Ser Pro Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
 115 120 125
 Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu
 130 135 140
 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
 145 150 155 160
 Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
 165 170 175
 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
 180 185 190
 Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr
 195 200 205
 Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro
 210 215 220
 Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro
 225 230 235 240
 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
 245 250 255
 Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn
 260 265 270
 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
 275 280 285
 Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val
 290 295 300
 Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
 305 310 315 320
 Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys
 325 330 335
 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu
 340 345 350
 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
 355 360 365
 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
 370 375 380

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
385 390 395 400

Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly
405 410 415

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
420 425 430

Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440

<210> 4
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 4

Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Tyr Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr Ser Ser Tyr Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

Phe Asn Arg Gly Glu Cys
210

<210> 5
<211> 1329
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic Polynucleotide

<400> 5
gagggtgcagc tgttggagtc tgggggaggc ttggtacagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt cactttcagt agctatgaca tgtcttgggt ccgccaggct 120
ccagggaagg ggctggagtg ggtctcaacc attagtgggt gtggtagtta cacctactat 180
caagacagtg tgaaggggcg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatac acagcctgag agccgaggac acggccgtat attactgtgc gtccccttac 300
tatgctatgg actactgggg gcaagggacc acggtcaccg tctcctcagc atccaccaag 360
ggcccatcgg tcttcccgtc agcaccctgc tccaggagca cctccgagag cacagccgcc 420
ctggggtgcc tgggtcaagga ctacttcccc gaaccagtga cgggtgtcgtg gaactcaggc 480
gccctgacca gcggcgtgca caccttcccc gctgtcctac agtcctcagg actctactcc 540
ctcagcagcg tggtgaccgt gccctccagc agcttgggca cgaagacctc cacctgcaac 600
gtagatcaca agcccagcaa caccaagggtg gacaagagag ttgagtccaa atatgggtccc 660
ccatgcccac catgcccagc acctgagttc ctgggggggac catcagtcctt cctgttcccc 720
ccaaaaccca aggacactct catgatctcc cggacccttg aggtcacgtg cgtgggtgggtg 780
gacgtgagcc aggaagacct cgagggtccag ttcaactgggt acgtggatgg cgtggagggtg 840
cataatgcca agacaaagcc gcgggaggag cagttcaaca gcacgtaccg tgtgggtcagc 900
gtcctcaccg tcctgcacca ggactgggtg aacggcaagg agtacaagtg caagggtctcc 960
aacaagggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg gcagccccga 1020
gagccacagg tgtacaccct gcccctatcc caggaggaga tgaccaagaa ccagggtcagc 1080
ctgacctgcc tgggtcaaagg cttctacccc agcgacatcg ccgtggagtg ggagagcaat 1140
gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1200
ttcctctaca gcaggctaac cgtggacaag agcagggtggc aggaggggaa tgtcttctca 1260
tgctccgtga tgcattgaggc tctgcacaac cactacacac agaagagcct ctccctgtct 1320
ctgggtaaa 1329

<210> 6
<211> 642

<212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic Polynucleotide

<400> 6
 gacatccagt tgaccagtc tccatccttc ctgtctgcat atgtaggaga cagagtcacc 60
 atcacttgca aggccagtc ggatgtgggt actgctgtag cctggatatca gcaaaaacca 120
 gggaaagccc ctaagctcct gatctattgg gcatccaccc tgcacactgg ggtcccatca 180
 aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct 240
 gaagattttg caacttatta ctgtcagcat tatagcagct atccgtggac gtttggccag 300
 gggaccaagc tggagatcaa acggactgtg gctgcacat ctgtcttcat cttcccgcca 360
 tctgatgagc aattgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 420
 cccagagagg ccaaagtaca gtggaagggt gataacgccc tccaatcggg taactcccag 480
 gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 540
 ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc 600
 ctcagctcgc ccgtcacaaa gagcttcaac aggggagagt gt 642

<210> 7
 <211> 116
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Polypeptide

<400> 7
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ser Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Gln Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Ser Pro Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val
 100 105 110
 Thr Val Ser Ser
 115

<210> 8
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<400> 8

Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Tyr Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Tyr Ser Ser Tyr Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Oligopeptide

<400> 9

Ser Tyr Asp Met Ser
1 5

<210> 10
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Oligopeptide

<400> 10

Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Gln Asp Ser Val Lys
1 5 10 15

Gly

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Oligopeptide

<400> 11

Pro Tyr Tyr Ala Met Asp Tyr
1 5

<210> 12
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Oligopeptide

<400> 12

Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala
1 5 10

<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Oligopeptide

<400> 13

Trp Ala Ser Thr Leu His Thr
1 5

<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Oligopeptide

<400> 14

Gln His Tyr Ser Ser Tyr Pro Trp Thr
1 5